Companies / ENP

ENTROPY NEURODYNAMICS LIMITED

ASX:ENPPharmaceuticals, Biotechnology & Life Sciences
1.63B shares on issueASX (delayed) · as of 28 July 2026$0.037price · delayed$60.4Mmarket cap · indicative
C
Dilution grade

Runway 2–4 quarters; options/rights overhang 68% of shares; 2 cash raises in 24 months

Cash runway3.6 quarters of funding
Share-count growth (24m)4.5%
Raise cadence (24m)2 cash raises
Options & rights overhang67.8% of shares
In-the-money supply34.5% of shares
Pending proposed issuesopen proposed issue (Appendix 3B)

ENTROPY NEURODYNAMICS LIMITED's ordinary share count was 1.63B as of June 2026, up 4.5% between January 2026 and June 2026. The company raised capital twice in the 24-month window for total disclosed proceeds of A$470K, most recently via a Prospectus - Options offer / Quotation in June 2026. Options and rights on issue could convert into 1.11B new shares, equal to 67.8% of the current share count, of which 34% are in the money; the nearest expiry is March 2027. At the June 2026 quarter the company reported A$5.1M in available cash, about 3.6 quarters of funding at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
67.8%
Max option dilution
34.5%
ITM option dilution
2
Raises · last 12 months
3.6 qtrs
Cash cover · 2–4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 1.63B per ASX (delayed) (28 July 2026).
1.61B1.62B1.63BNov 25Mar 26July 26Cash raise · 25 June 2026Cash raise · 16 Feb 2026

Cash runway

3.6 qtrs
Two to four quarters of funding at the recent spend rate.
$5.1M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
26 June 20262A · quoted issueENP : ORDINARY FULLY PAID1.63BAppendix 2A
29 May 20262A · quoted issueENP : ORDINARY FULLY PAID1.63BAppendix 2A
15 May 20263H · cancellationENP : ORDINARY FULLY PAID1.58BAppendix 3H
17 Apr 20262A · quoted issueENP : ORDINARY FULLY PAID1.58BAppendix 2A
14 Apr 20262A · quoted issueENP : ORDINARY FULLY PAID1.58BAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

2 cash raises in the last 24 months · 2 in the last 12 months

—
Prospectus - Options offer / Quotation
25 June 2026 ACTIVE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

67.8%
Total overhang · of current shares
34.5%
In the money · at current price
1.11B
Potential new shares
Mar 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
13 May 2026Jason CarrollBuy——$19k3Y notice
12 May 2026Jason CarrollBuy750k—$26k3Y notice
14 Apr 2026Herwig JanssenOther1.5M—$50k3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

26 July 2026Techknow Invest Roadshow presentation
24 July 2026Appointment of Joint Company Secretary
21 July 2026$PQuarterly Activities Report and Appendix 4C
19 July 2026$PSouth Africa Grants ENP Broad Fibromyalgia Patent to 2043
9 July 2026Additional Australian patent granted
9 July 2026Investor Presentation
6 July 2026$P100% Clinical improvement, 50% Remission in BED study
2 July 2026$PTrading Halt
26 June 2026Application for quotation of securities - ENP
26 June 2026Top 20 Option Holders & Distribution Schedule
25 June 2026Proposed issue of securities - ENP
25 June 2026Short Form Prospectus
14 June 2026$PDSMB Clears TRP 8803 to Advance to Cohort 2
1 June 2026$PEntropy completes Cohort 1 dosing in BED trial
29 May 2026Application for quotation of securities - ENP
22 May 2026Release of Securities from Escrow
15 May 2026Notification of cessation of securities - ENP
13 May 2026Change of Director's Interest Notice - JC
10 May 2026Australian Microcap Investment Conference presentation
4 May 2026$PEntropy files new US patent for IBS program

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.